Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
Please note the ANZCTR will be unattended on Monday the 7th of October for the Labour Day public holiday.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623000096651
Ethics application status
Approved
Date submitted
25/10/2022
Date registered
27/01/2023
Date last updated
16/06/2024
Date data sharing statement initially provided
27/01/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Query!
Scientific title
LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Query!
Secondary ID [1]
308189
0
CTC0378
Query!
Secondary ID [2]
308190
0
COGNO2201
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
LUMOS2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Grade 2 Glioma
327930
0
Query!
Grade 3 Glioma
327931
0
Query!
Condition category
Condition code
Cancer
324999
324999
0
0
Query!
Brain
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Participants who consent to the study, will have a study-specific craniotomy and the tissue collected will be used to undergo molecular testing to identify mutations. The results of molecular testing will be reviewed by the LUMOS2 Molecular Tumour Advisory Board, and a treatment recommendation will be provided. If the participant is found to have a molecular profile that matches to one of the treatment arms available, they will be consented to and screened for the matched treatment arm. If the participant does not have a molecular profile that matches a treatment arm, they will be randomised to one of the treatment arms that does not require a matched mutation.
The following treatment arms are available under this protocol:
Arm 1 - Paxalisib: 45mg taken orally (capsule), once daily, for a 28 day cycle. If tolerated, after cycle 1 this will increase to 60mg daily.
Arm 2 - AK104: 6mg/kg as Intravenous injection, once every 2 weeks
Arm 3 - Selinexor: 80mg taken orally (tablet), once daily
Participants will continue to receive treatment until disease progression is documented or when the participants experience intolerable toxicity or withdraw for another reason.
Query!
Intervention code [1]
324641
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
332811
0
Progression free survival at 6 months
Query!
Assessment method [1]
332811
0
Query!
Timepoint [1]
332811
0
Progression Free Survival is defined as the time from the date of study enrolment to date of first documented evidence of disease progression or death from any cause. This is assessed via 8 weekly MRI scans until disease progression/death and will be estimated using the Kaplan-Meier method.
Query!
Secondary outcome [1]
414763
0
Overall survival
Query!
Assessment method [1]
414763
0
Query!
Timepoint [1]
414763
0
For the duration of the study. From the date of first diagnosis to date of death from any cause, or the date of last known follow-up alive
Query!
Secondary outcome [2]
414764
0
Overall objective Response (OOR) Rate assessed by modified RANO criteria
Query!
Assessment method [2]
414764
0
Query!
Timepoint [2]
414764
0
ORR is the proportion of participants who achieve partial or complete response, as assessed by 8-weekly MRI scans prior to disease progression/death
Query!
Secondary outcome [3]
414765
0
Health Related Quality of Life using the EORTC QLQ-C30 questionnaires
Query!
Assessment method [3]
414765
0
Query!
Timepoint [3]
414765
0
Every 4 weeks from first dose of study treatment until participants stop treatment due to intolerable toxicity or withdraws for another reason apart from disease progression. After treatment discontinuation, the health-related quality of life will be assessed at every 12 weeks until disease progression.
Query!
Secondary outcome [4]
417745
0
Health Related Quality of Life using the EORTC BN20 questionnaire
Query!
Assessment method [4]
417745
0
Query!
Timepoint [4]
417745
0
Every 4 weeks from first dose of study treatment until participants stop treatment due to intolerable toxicity or withdraws for another reason apart from disease progression. After treatment discontinuation, the health-related quality of life will be assessed at every 12 weeks until disease progression.
Query!
Eligibility
Key inclusion criteria
Molecular profiling:
1. Adults, aged 18 years and older
2. Histologically confirmed glioma, IDH-mutant, histologically grade 2 or 3 at initial diagnosis (i.e., without necrosis or microvascular proliferation); including CDKN2A/B homozygous deleted IDH-mutant astrocytomas but not IDH-wildtype diffuse astrocytomas with any of TERT promoter mutation, EGFR amplification and/or +7/-10 copy number changes (i.e., molecular features of glioblastoma).
3. Has evidence of progressive disease (defined as new contrast-enhancing tumour and/or 25% increase in the size of the T2/FLAIR area compared to prior imaging after prior treatment with radiotherapy and chemotherapy; with a clinical indication for neurosurgery).
4. Prior treatment with radiotherapy and alkylating chemotherapy, defined as either sequential therapy with CNS radiotherapy then an akylating agent, or concurrent CNS radiotherapy with an alkylating agent.
5. ECOG performance status 0-2.
6. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments; It is the intention that molecular profiling is performed for patients who are in principle wishing to take part in a treatment arm if they are found to be eligible following molecular profiling.
7. Signed, written informed consent (LUMOS2 molecular profiling and linkage to Medicare records).
Additional inclusion criteria for:
Arm 1 - Paxalisib:
1. Histologically confirmed glioma, IDH-mutant, histologically grade 2 or 3 at initial diagnosis (i.e., without necrosis or microvascular proliferation); including CDKN2A/B homozygous deleted IDH-mutant astrocytomas but not IDH-wildtype diffuse astrocytomas with any of TERT promoter mutation, EGFR amplification and/or +7/-10 copy number changes (i.e., molecular features of glioblastoma).
2. Adequate recovery from surgery in the opinion of the treating physician (as evidenced by ECOG performance status 0-2).
3. Adequate organ system function post-surgery as assessed by the following minimal laboratory requirements.
a) Bone marrow function; platelets greater than or equal to 100 x 109/L, ANC greater than or equal to 1.5 x 109/L, and haemoglobin greater than or equal to 90g/L (5.6mmol/L)
b) Liver function; ALT/AST less than or equal to 3 x ULN and total bilirubin less than or equal to 1.5xULN
c) Renal function; serum creatinine less than or equal to 1.5xULN
4. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.
5. LUMOS2 Molecular Tumour Advisory Panel (MTAP) report confirming eligibility to this treatment arm.
6. Signed, written informed consent
Arm 2 - AK104:
1. Histologically confirmed glioma, IDH-mutant, histologically grade 2 or 3 at initial diagnosis (i.e., without necrosis or microvascular proliferation); including CDKN2A/B homozygous deleted IDH-mutant astrocytomas but not IDH-wildtype diffuse astrocytomas with any of TERT promoter mutation, EGFR amplification and/or +7/-10 copy number changes (i.e., molecular features of glioblastoma).
2. Adequate recovery from surgery in the opinion of the treating physician (as evidenced by ECOG performance status 0-2).
3. Adequate organ system function post-surgery as assessed by the following minimal laboratory requirements
a. Bone marrow function; platelets greater than or equal to 100 x 109/L, ANC greater than or equal to 1.5 x 109/L, and haemoglobin greater than or equal to 90g/L (5.6mmol/L).
b. Liver function; ALT/AST less than or equal to 3 x ULN and total bilirubin less than or equal to 1.5xULN.
c. Renal function; serum creatinine less than or equal to 1.5xULN.
4. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments; and
5. LUMOS2 Molecular Tumour Advisory Panel (MTAP) report confirming eligibility to this treatment arm
6. Signed, written informed consent.
Arm3 - Selinexor:
1. Histologically confirmed glioma, IDH-mutant, histologically grade 2 or 3 at initial diagnosis (i.e., without necrosis or microvascular proliferation); including CDKN2A/B homozygous deleted IDH-mutant astrocytomas but not IDH-wildtype diffuse astrocytomas with any of TERT promoter mutation, EGFR amplification and/or +7/-10 copy number changes (i.e., molecular features of glioblastoma).
2. Adequate recovery from surgery in the opinion of the treating physician (as evidenced by ECOG performance status 0-2).
3. Adequate organ system function post-surgery as assessed by the following minimal laboratory requirements (within 7 days prior to first administration of study drug).
a) Bone marrow function; platelets greater than or equal to 100 x 109/L, ANC greater than or equal to 1.5 x 109/L, and haemoglobin greater than or equal to 90g/L (5.6mmol/L).
b) Liver function; ALT/AST less than or equal to 3 x ULN and total bilirubin less than or equal to 1.5xULN.
c) Renal function; serum creatinine less than or equal to 1.5xULN.
4. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments; and
5. LUMOS2 Molecular Tumour Advisory Panel (MTAP) report confirming eligibility to this treatment arm
6. Signed, written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Molecular profiling:
1. Prior treatment with bevacizumab
2. Intra-surgical treatments (e.g., oncolytic virus administration, Gliadel wafers) at their last craniotomy prior to study enrolment.
3. Comorbidities or conditions (e.g., psychiatric) that may compromise assessment of key outcomes or in the opinion of the physician limit the ability of the participant to comply with the protocol.
4. Unable (e.g., due to pacemaker or ICD device) or unwilling to have a contrast-enhanced MRI of the head
5. Any unresolved toxicity (>CTCAE grade 2) from previous anti-cancer therapy (Those with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy))
6. Pregnancy, lactation, or inadequate contraception. Persons who are able to become pregnant, and having sexual relationships in which they may become pregnant, must use a reliable means of contraception and must have a negative pregnancy test done within 7 days prior to registration. Persons who are having sexual relationships in which their partner may become pregnant must have been surgically sterilised or use a (double if required) barrier method of contraception.
Additional exclusion criteria for:
Arm 1 - Paxalisib:
1. Intra-surgical treatments (e.g., oncolytic virus administration, Gliadel wafers) at their last craniotomy prior to study enrolment;
2. Presence of any metastatic tumours at the time of craniotomy that are not consistent with original glioma diagnosis.
3. Prior IDH inhibitor therapy within 4 weeks of first dose of LUMOS2 investigational treatment.
4. Prior investigational agents within 4 weeks of first dose of LUMOS2 investigational treatment.
5. Concomitant medications which may interact with the investigational product(s) in the opinion of the physician
6. Baseline QT interval >470msec or clinically significant cardiac history (myocardial infarction or symptomatic bradycardia, active congestive heart failure or angina pectoris).
Arm 2 - AK104:
1. Intra-surgical treatments (e.g., oncolytic virus administration, Gliadel wafers) at their last craniotomy prior to study enrolment
2. Presence of any metastatic tumours at the time of craniotomy that are not consistent with original glioma diagnosis.
3. Prior IDH inhibitor therapy within 4 weeks of first dose of LUMOS2 investigational treatment.
4. Prior investigational agents within 4 weeks of first dose of LUMOS2 investigational treatment.
5. Concomitant medications which may interact with the investigational product(s) in the opinion of the physician.
6. Clinically significant symptomatic auto-immune disease that may predispose patient to immune-related adverse events in the opinion of the treating physician.
Arm3 - Selinexor:
1. Intra-surgical treatments (e.g., oncolytic virus administration, Gliadel wafers) at their last craniotomy prior to study enrolment;
2. Presence of any metastatic tumours at the time of craniotomy that are not consistent with original glioma diagnosis.
3. Prior IDH inhibitor therapy within 4 weeks of first dose of LUMOS2 investigational treatment.
4. Prior investigational agents within 4 weeks of first dose of LUMOS2 investigational treatment.
5. Concomitant medications which may interact with the investigational product(s) in the opinion of the physician.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
The results of the participant's molecular sequencing will be used to allocate the participants to the study treatment arms. If the participant does not have a mutation that has a targeted treatment, the participant will be randomised to a treatment arm that does not require a matched mutation.
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
LUMOS2 is a multi-arm, phase 2, biomarker-directed, signal-seeking, umbrella clinical trial.
Prior studies in similar populations have shown 6-month Progression Free Survival (PFS) of approximately 36% (range 30-40%) and a rate lower than this would not be considered worthwhile. Nineteen participants will be recruited into each treatment arm, and have 80% power at 5% one-sided alpha to rule out a rate of 36% if the true rate is 65%, using a one-sample exact binomial test, and will allow estimation of 6-month PFS with a 95% confidence interval of maximum width ±21%.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
29/09/2023
Query!
Actual
11/09/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
57
Query!
Accrual to date
2
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS,VIC
Query!
Recruitment hospital [1]
23373
0
Austin Health - Austin Hospital - Heidelberg
Query!
Recruitment hospital [2]
23438
0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Query!
Recruitment hospital [3]
23439
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment hospital [4]
23440
0
Peter MacCallum Cancer Centre - Melbourne
Query!
Recruitment hospital [5]
23441
0
Monash Medical Centre - Clayton campus - Clayton
Query!
Recruitment hospital [6]
23442
0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Query!
Recruitment hospital [7]
23443
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [8]
23444
0
Royal Brisbane & Womens Hospital - Herston
Query!
Recruitment hospital [9]
25937
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [10]
25938
0
Calvary Mater Newcastle - Waratah
Query!
Recruitment hospital [11]
25939
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment postcode(s) [1]
38841
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
38842
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
41770
0
2170 - Liverpool
Query!
Recruitment postcode(s) [4]
41771
0
2298 - Waratah
Query!
Recruitment postcode(s) [5]
38843
0
3000 - Melbourne
Query!
Recruitment postcode(s) [6]
38845
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [7]
38758
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [8]
38844
0
3168 - Clayton
Query!
Recruitment postcode(s) [9]
38847
0
4029 - Herston
Query!
Recruitment postcode(s) [10]
41772
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [11]
38846
0
7000 - Hobart
Query!
Funding & Sponsors
Funding source category [1]
312445
0
Government body
Query!
Name [1]
312445
0
Australian Government, Department of Health and Aged Care - Medical Research Future Fund
Query!
Address [1]
312445
0
16 Marcus Clarke St, Canberra ACT 2601
Query!
Country [1]
312445
0
Australia
Query!
Primary sponsor type
University
Query!
Name
The University of Sydney
Query!
Address
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450
Query!
Country
Australia
Query!
Secondary sponsor category [1]
314023
0
None
Query!
Name [1]
314023
0
Query!
Address [1]
314023
0
Query!
Country [1]
314023
0
Query!
Other collaborator category [1]
282456
0
Other Collaborative groups
Query!
Name [1]
282456
0
Cooperative Trials Group for Neuro-Oncology
Query!
Address [1]
282456
0
NHMRC Clinical Trials Centre
Level 6, Lifehouse
119-143 Missenden Road
Camperdown, NSW 2050
Query!
Country [1]
282456
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
311791
0
Sydney Local Health District Ethics Review Committee (RPAH Zone)
Query!
Ethics committee address [1]
311791
0
Suite 210A RPA Medical Centre Cnr Missenden Road and Carillon Avenue NEWTOWN NSW 2042
Query!
Ethics committee country [1]
311791
0
Australia
Query!
Date submitted for ethics approval [1]
311791
0
25/10/2022
Query!
Approval date [1]
311791
0
24/01/2023
Query!
Ethics approval number [1]
311791
0
2022/ETH02230
Query!
Summary
Brief summary
This study aims to evaluate a new approach to the treatment of patients with lower grade glioma that has started to grow again (i.e. is recurrent) following your initial treatment. Who is it for? You may be eligible to join this study if you are aged 18 years or older, with histologically-confirmed grade 2 or 3 glioma at initial diagnosis, and with evidence of progressive disease after initial treatment. Study details For each participant, the study will involve taking a sample of tumour tissue during surgery, which will be screened for biomarkers. The results of this testing will then be used by a panel of experts who will make a treatment recommendation. If you have a mutation that matches one of the treatment arms, this will be recommended to you. If you do not have a mutation that matches one of the treatment arms, you will be randomised (i.e. allocated by chance) to one of the treatments that does not require a matching mutation. The study treatments available in LUMOS2 are: the oral medication Paxalisib administered once daily, the intravenous infusion AK104 administered once every 2 weeks, or the oral medication Selinexor administered once daily. Treatment will continue until disease progression is documented or until participants experience intolerable toxicity or withdraw for another reason. During treatment, participants will undergo an MRI scan every 8 weeks to assess for disease progression and response to treatment, and will complete questionnaires regarding their quality of life. It is hoped that screening tumour tissue for specific biomarkers to direct targeted treatment will be effective, safe, and cost-effective for the management of patients with recurrent lower grade glioma.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
122378
0
Prof Hui Gan
Query!
Address
122378
0
Austin Health, 145 Studley Road, Heidelberg, VIC, 3084
Query!
Country
122378
0
Australia
Query!
Phone
122378
0
+61 3 9496 5000
Query!
Fax
122378
0
Query!
Email
122378
0
hui.gan@onjcri.org.au
Query!
Contact person for public queries
Name
122379
0
LUMOS2 Coordinator
Query!
Address
122379
0
NHMRC Clinical Trials Centre
Lifehouse Level 6
119–143 Missenden Road
Camperdown NSW 2050
Query!
Country
122379
0
Australia
Query!
Phone
122379
0
+61 2 9562 5000
Query!
Fax
122379
0
Query!
Email
122379
0
lumos2.study@sydney.edu.au
Query!
Contact person for scientific queries
Name
122380
0
LUMOS2 Coordinator
Query!
Address
122380
0
NHMRC Clinical Trials Centre
Lifehouse Level 6
119–143 Missenden Road
Camperdown NSW 2050
Query!
Country
122380
0
Australia
Query!
Phone
122380
0
+61 2 9562 5000
Query!
Fax
122380
0
Query!
Email
122380
0
lumos2.study@sydney.edu.au
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Participant data supporting the publication results and participant data relating to primary outcomes, secondary outcomes, and safety data.
Query!
When will data be available (start and end dates)?
Data are available straight after publication
Data are available for an indefinite time
Start date: 31 Jul 2027(approx)
End date: Unknown
Query!
Available to whom?
Data are potentially available to:
- Researchers from not-for-profit organisations
- Commercial organisations
- Other
Based in:
- Any location
Further information:
All data requests will be considered by the primary sponsor on a case by case basis. Requests must include a methodologically sound proposal. Specific conditions of use may apply and will be specified in a data sharing agreement (or similar) that the requester must agree to before access is granted. For further information, please contact lumos2.study@sydney.edu.au.
Query!
Available for what types of analyses?
Any type of analysis and will be assessed on a case-by-case basis
Query!
How or where can data be obtained?
Please contact the LUMOS2 study team, at lumos2.study@sydney.edu.au
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF